 Home > Active Ingredient News > Drugs Articles > The glory and dream of JPM's top 20 domestic pharmaceutical companies: who can become the medicine king?

The glory and dream of JPM's top 20 domestic pharmaceutical companies: who can become the medicine king?

 Last Update: 2023-02-01
 Source: Internet
 Author: User

Tags

trazodone drug

forest green house

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

2022 can be said to be a difficult year
for the biopharmaceutical field.
However, there is no eternal darkness, only the dawn
that has not yet arrived.

With the arrival of 2023, the biopharmaceutical industry has also started a new year
.
In the new year, pharmaceutical companies are beginning to set a new direction
for future development.

From January 9 to January 12, biopharmaceutical companies from all over the world gathered across the ocean in the United States to summarize past achievements and outline their outlook
for the future at the JPMorgan Healthcare Conference (JPM).

Many excellent domestic pharmaceutical companies participated in it and released information
about future development.

For example, BeiGene said that 10 new molecules will enter the clinic each year starting in 2024; Not to be outdone, Innovent Biologics has proposed a target of 20 billion yuan in 4-5 years; Junshi Biologics said that nearly 10 new drugs will be approved
in the next three years.

These pharmaceutical companies are the backbone of the development of
China's pharmaceutical industry.
So, who sets the grand goal and can achieve it first?

Who are you most optimistic about? You can tell everyone your answer
in the voting area below.

/ 01 /

BeiGene:

From 2024, 10 new molecules will enter the clinic every year

In the decade from 2010 to 2020, BeiGene has had a lot
to offer.

The company's self-developed BTK inhibitor zebratinib, PD-L1 inhibitor tislelizumab, and PARP inhibitor pamiparib three products have been launched
.

For BeiGene, the main goal is to go to sea
.
The company said that in 2023, zebratinib will also receive CLL/SLL indications in the United States, Canada and Australia, and CLL/SLL in the domestic first-line CLL Indications will also be approved; Tislelizumab will be approved by regulators in the United States, Australia and Europe, and in China, it will win the three first-line treatment indications of gastric cancer, esophageal squamous
cell carcinoma and hepatocellular carcinoma.

In addition to mature products, BeiGene's many drug candidates are also worth looking forward to
.

The BCL-2 inhibitor BGB-11417 is expected to read clinical results in the second quarter of 2023; The much-watched TIGIT monoclonal antibody Ociperlimab will also be available in 2023 Stage 2 efficacy data for multiple cancer types were read out annually; Data for the PROTAC drug BGB-16673 will also be read out
in 2023.

In addition, BeiGene expects more than 4 new molecular entities to enter clinical development in 2023 and more than 10 new molecules per year starting in 2024
.

/ 02 /

China Biopharma:

40 innovative drugs are expected to be on the market by 2030

China Biopharma, which participated in the JPM conference for the first time, said that it will fully transform
to innovation in the future.
At this stage, Chinese biopharmaceuticals are transforming from generic-driven pharmaceutical companies to innovation-driven companies
.

In the field of oncology, anlotinib, a multi-target tyrosine kinase inhibitor developed by Chia Tai Tianqing, a subsidiary of Chinese biopharmaceuticals, has been approved in China for the treatment of advanced non-small cell lung cancer, soft tissue sarcoma, small cell lung cancer and other indications
.

In addition, China Biopharmaceutical has 37 innovative anti-tumor drugs in the clinical stage, covering IDH2, TIM-3, CDC7, BCL-2, CD47, IAP and other innovative targets that have attracted much attention
.

Among them, three products, tyrosine kinase ALK/cMet inhibitor, ALK/c-Met selective inhibitor and long-acting G-CSF, have been declared for marketing
.
China Biopharma is expected to be by 2030 40 new drug candidates in the pipeline will be launched
one after another.

While advancing its own pipeline, China Biopharma also expects to reach 10 to 15 blockbuster BD projects in the next three years, each product candidate has the potential
to peak sales of 1.
5 billion yuan and more than 2 billion yuan.

China's hope for the future is to achieve China's TOP3 in the four major therapeutic areas, and strive to rank among the top 30 pharmaceutical companies
in the world by 2030.

/ 03 /

Junshi Biologics:

Nearly 10 new drugs are targeted for approval in the next three years

From 2012 to 2022, Junshi Biologics will not only base itself in China, but also synchronize global R&D
.

At present, Junshi PD-1 inhibitor teripulimab has been approved for 6 indications in China, and its marketing application
has been accepted by the US FDA and EMA in Europe.

For the new crown drug V116, which has attracted much attention, Junshi also made a report, and it is reported that VV116 will be the first in Shanghai hospitals to begin to be used in the form of compassionate medicine for the treatment of new crown patients
.

In terms of commercialization, Junshi Biologics has completed the adjustment of the commercialization team, which has more than 1,100 people, and its product teripulimab has been sold
in more than 4,000 medical institutions and nearly 2,000 professional pharmacies and social pharmacies across the country.

At present, Junshi Biologics has created 6 drug types, 5 treatment types, more than 50 products under research at different stages, and more than 100 clinical studies are underway, covering nearly 10,000 patients
in more than 10 countries and regions around the world.

Looking ahead, in 2022-2023, Junshi Biologics will have 3 new molecular entities approved for marketing, including senaparib
, a PARP inhibitor jointly developed with Yingpai Pharmaceutical.

During the same period, the products under development are expected to be approved for more than 10 indications, covering rheumatoid arthritis, ankylosing spondylitis, psoriasis, first-line treatment of esophageal squamous cell carcinoma, first-line treatment of liver cancer, small cell lung cancer, Crohn's disease, etc
.

In 2024-2025, Junshi expects five new molecular entities to be approved for marketing, including anti-PCSK9 monoclonal antibody, anti-BTLA monoclonal antibody, anti-IL-17A monoclonal antibody, and targeted EGFR exon JS20 of 111, etc
.
After 2025, more than 10 new molecular entities will be approved for listing
.

/ 04 /

Legendary Creatures:

From hematological tumors to solid tumors, challenge incurable diseases

The past 2022 has been a crucial year
for legendary creatures.

In 2022, BCMA of legendary creatures CAR-T therapy cedarchicel has been approved for marketing in the United States, Japan, the European Union and other places for the treatment of multiple myeloma
.
In December 2022, the listing application of Cedakicel in China was also accepted
.

For Cedaraki Orensey, the journey has just begun
.
At the JPM conference, Legendary Biologics partner Johnson & Johnson introduced a comprehensive presentation of cedarcel's global clinical development program, including a series of clinical programs
for end-line and front-line treatment of multiple myeloma.

Of course, the ambitions of legendary creatures do not stop there
.
It is well known that CAR-T therapy does not work well
against solid tumors.
And the ambition of legendary creatures is to conquer solid tumors
.

At present, Legend Biotech has established core technology platforms in three major fields: CAR-T, CAR-NK and CAR-γδT, and has 10 pipeline projects covering malignant hematological tumors and solid tumors
.

Among them, Legendary Bio highlighted the first CAR-T therapy LB1908 targeting Claudin18.
2 (and the other CAR-T therapy LB2102
targeting δ-like ligand 3).

/ 05 /

Innovent Biologics:

The revenue target in 4-5 years is 20 billion yuan

2022 is the first year
of the development of the new decade for Innovent Biologics.

In the past 11 years, Innovent has successfully launched 8 products, and more than 20 product pipelines have been continuously advanced to different clinical stages
such as new drug market review, pivotal clinical and proof-of-concept (PoC).

In particular, the highly anticipated GLP1/GCGR agonist IBI362 has strong Phase 2 clinical data in both indications of obesity and diabetes and has entered the Phase 3 registered clinical study
.

In terms of research and development, the discovery platform of Guoqing Institute has 300 scientists, successfully delivered 6 innovative molecules, and independently established multiple technology platforms
.

2023 will be a year of rapid growth for Innovent Biologics, BCMA CAR-T therapy IBI326, PCKS9 inhibitor IBI306, PI3Kδ inhibitor IBI376 are all expected to be available
in 2023.

In the future, Innovent will continue to strengthen its competitiveness and expects to have 15-20 products
on the market in 2027.
Innovent expects to reach RMB20 billion in operating revenue within 4-5 years
.

/ 06 /

Remegen Biologics:

15 products under development have carried out 30+ clinical trials at home and abroad

Since its establishment in 2008, Remegen has grown into a global biopharmaceutical company with BLyS/APRIL dual-target fusion proteins Tatacept and HER2 ADC vedicitumab was approved for three indications in two products
.

Remegen is also continuing to expand the indications
of these two products.
Tataercept has initiated a global Phase 3 clinical trial for SLE in 2022, a Phase 2 clinical study for indications such as IgA nephropathy, Sjogren's syndrome, myasthenia gravis and other indications have achieved positive results, and a Phase 3 clinical study
is being initiated or will soon be initiated in China or the United States.

Phase 3 clinical studies of vedicitumab combined with anti-PD-1 antibody for the first-line treatment of urothelial carcinoma, vedicitumab for HER2-low breast cancer, and HER2-high expression breast cancer with liver metastasis are underway
.

In addition to existing products, Remegen has established a steadily developing R&D pipeline, and about 15 products under development are currently carrying out 30+ clinical trials at home and abroad, covering the three therapeutic areas
of autoimmune diseases, oncology and ophthalmology.
These include ADCRC88 targeting mesothelin, anti-PD-L1 monoclonal antibody RC98, ADC drug RC108 targeting c-MET, ADC product RC118 targeting Claudin18.
2, and VEGF/FGF dual-target fusion protein RC28
.

In 2023, Remegen expects to initiate a Phase III clinical study
of RC28 for the treatment of wet age-related macular degeneration.

/ 07 /

Akeso:

Phase III clinical trial of AK112 will be initiated in 2023-2024

On December 6, Akeso announced its partnership with Summit Therapeutics entered into a partnership agreement in which Akeso acquired rights to Akeso's PD-1/VEGF dual antibody AK112 in the United States, Canada, Europe, Canada and Japan
.
Currently, AK112 has become Summit Core assets
.

At the JPM Annual Meeting, Summit This cooperation and its follow-up plans
were also highlighted.
Summit plans to initiate Phase III clinical
trials of Ivonescimab in 2023-2024, either alone or in collaboration with Akeso.

/ 08 /

CanSino Biologics:

Actively promote the global innovation strategy

Over the past 14 years, CanSino Biologics has continued to develop advanced vaccine products based on five major technology platforms: viral vector vaccine technology, synthetic vaccine technology, protein structure design and VLP recombinant technology, mRNA vaccine technology, preparation and drug delivery technology, and obtained more than 30 invention patents
.

CanSino already has a number of products on the market
.
It is worth mentioning that in 2022, CanSino's world's first inhaled new crown vaccine has successively obtained emergency use authorization
from China and Morocco.
In addition, the new coronavirus mRNA vaccine CS-2034, developed based on the mature mRNA vaccine technology platform, has also obtained positive stage data
recently.

At present, CanSino has established dozens of innovative vaccine product R&D pipelines for more than ten diseases, covering the prevention
of a series of diseases such as novel coronavirus pneumonia, meningitis, diphtheria, tetanus, pneumonia, tuberculosis and so on.

/ 09 /

Simcere Pharmaceutical:

Join hands with Hainan Lecheng to promote the "Lecheng Plan"

As an established pharmaceutical company, Simcere Pharmaceutical's owners play BD strategy
.

Simcere Pharmaceutical, together with the Lecheng Authority, held a special JPM promotion seminar in the United States to promote more innovative drugs from all over the world to enter the Chinese market through the "green channel" of the Lecheng Pilot Zone and benefit more Chinese patients
.

Up to now, 9 international innovative pharmaceutical and device products have been approved for marketing
in China by using Lecheng real-world data to assist clinical evaluation.

Among them, Simcere Pharmaceutical and G1 Traracicil hydrochloride hydrochloride, a full-range bone marrow protection innovative drug co-developed by Therapeutics, was successfully approved for marketing in China in July 2022, only one year and five months
after the drug was approved in the United States.

/ 10 /

Zai Lab:

It is expected to be profitable in 2025

After 8 years of development, Zai Lab has now established a differentiated product pipeline
.

At present, Zai Lab has launched four products: PARP inhibitor niraparib, tumor electric field therapy device Epdun, KIT/PDGFRα kinase switch regulation inhibitor repatinib, and new antibiotic omacycline tosylate
.
In addition, Zai Lab has 50+ clinical trials underway/planned
.

In 2023, Zai Lab's many drug candidates are also worth looking forward to
.

Zai Lab expects that efgartigimod, an FcRn antagonist for the treatment of systemic myasthenia gravis, and durlobactam, a combination of β-lactam/β-lactamase inhibitors for infections caused by carbapene-resistant strains, are expected to be approved for marketing
in China in 2023.

In addition, Zai Lab said it will submit at least one clinical application each year, and more than eight products with first-in-class and best-in-class potential will be available
in the next three years.

At the same time, Dr.
Du Ying said that it is expected to achieve commercial profitability by 2023 and overall profitability
by the end of 2025.

/ 11 /

InnoCare:

Thirteen products are in clinical development

InnoCare's vision is to become a global leader in biopharmaceuticals, focusing on oncology and autoimmunity to develop innovative therapies
for patients around the world.

In 2023, InnoCare's flagship product BTK inhibitor orelabrutinib is expected to be approved in China for the treatment of patients with relapsed/refractory Fahrenhet macroglobulinemia and relapsed/refractory marginal zone lymphoma
.

At present, InnoCare has 13 products in the field of hematological tumors, solid tumors and autoimmune diseases in the clinical development stage, including BTK inhibitors, anti-CD19 monoclonal antibodies, targeted protein degraders, BCL2 inhibitors, SHP2 allosteric inhibitors, etc
.

Among them, 6 innovative drugs entered the first clinical phase in 2022
.
The anti-CD19 antibody tafasitamab plans to complete the key registration study for relapsed/refractory DLBCL in 2023 and apply for marketing
in China.

/ 12 /

Hutchison Pharmaceutical:

It is in the transition period, and the pipeline is prioritized in the middle and late stages

Hutchison is actively making a strategic shift to focus on the most cutting-edge drugs in its in-house pipeline that are most likely to drive near-term value, allowing the company to focus its resources on its late-stage drugs, particularly the international presence
of fruquintinib.

Fruquintinib is a highly selective and potent oral VEGFR Inhibitors, monotherapy has been approved in China for the treatment of metastatic colorectal cancer
.
Currently, Hutchison is exploring the therapeutic potential
of fruquintinib globally.
In the first half of 2023, Hutchison is expected to complete the submission of fruquintinib new drug marketing applications
to EMA and PMDA.

In terms of research and development, in the first half of last year, Hutchison launched six new clinical trials and continued to expand its own oncology drug commercial team in China, with about 820 employees, covering about 3,000 cancer hospitals and about 30,000 oncologists
.

Next, Hutchison will further enhance and promote the commercialization of its independent innovative drugs, expand production capacity, and accelerate the international layout
of fruquintinib, sevotinib and other products.

/ 13 /

Nova Health:

Early prevention and treatment of cancer through screening

In 2022, Nova Health's commercialization capabilities were further confirmed
.
A few days ago, Nuohuijian issued an announcement that it is expected that the total revenue in 2022 is expected to be 766 million, a year-on-year increase of 260%.

At the same time, the company's profitability is improving
.
Nova Health expects the annual gross margin to be between 81.
6% and 87.
4%, a significant increase
from 72.
7% in 2021.

For Nova Health, the future will still move forward in the field of early screening
.

Nova Health said that in terms of pan-cancer screening, the company has launched a PANDA (China Pan-Cancer Early Detection) clinical project in China, targeting more than 22 cancer types
.
The PANDA program consists of 4 clinical phases and is partnered with Peking University Health Science Center to recruit 50,000 participants
over 6 years.

At the same time, in the three years from 2023 to 2025, Nova Health plans to carry out a number of R&D value creation activities
.

/ 14 /

Ascentage Pharma:

From Biotech to Biopharma

Under the "Global Innovation" strategy, Ascentage Pharma has made a number of breakthroughs and further moved from Biotech to Biopharma
.

In terms of mature products, Ascentage Pharma's orebatinib has been approved for the treatment of chronic myeloid leukemia (CML)
with T315I mutation.
Currently, the marketing application of orebatinib for the treatment of patients with chronic myeloid leukemia chronic phase (CML-CP) who are resistant and/or intolerant to first- and second-generation tyrosine kinase inhibitors (TKIs) has been accepted by CDE and included in the priority review

In terms of the future, Ascentage Pharma already has 9 small molecule new drugs in clinical development, including Bcl-2 inhibitors and targeted PROTAC drugs
.
These drugs are undergoing more than 50 Phase 1/2 clinical trials
in China, the United States, Australia, Europe and Canada.

Among them, APG-2575, a blockbuster product of the apoptosis pipeline, has carried out 19 clinical studies worldwide, including the key registration phase 2 clinical trial for the treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, and the first patient has been dosed
.

The EED inhibitor APG-5918 also entered the clinical phase
in 2022.
In addition, Ascentage Pharma also introduced the relevant clinical progress
of multiple varieties, including MDM2-p53 inhibitor APG-115, IAP antagonist APG-1387, and Bcl-2/Bcl-xL inhibitor APG-1252.

/ 15 /

Antengene:

Focus on breakthrough therapies and lay out differentiated pipelines

Antengene is confident that it will become a multi-product company in the next 3-5 years
.

At present, focusing on hematology and solid tumors, the company has created a pipeline of complementary internal assets and characteristic products with explosive potential, including CD24 monoclonal antibody, ERK1/2 inhibitor, PD-1/4-1BB bi-antibody, ATR inhibitor, CD73 small molecule inhibitor, and Claudin 18.
2 Antibody conjugate drug monoclonal antibody and other products
.

Among them, Claudin 18.
2 The ADC drug ATG022 is planned to conduct a global multi-center Phase I clinical study
of ATG-022 in Australia, China and the United States.
Currently, it has obtained trial approval in Australia, and INDPD-L1/4-1BB dual antibody ATG-101 has been approved for Phase I clinical trial application in Australia, the United States and China in December 2022 for the treatment of advanced or metastatic solid tumors and non-Hodgkin lymphoma (NHL).

In the first half of 2023, Antengene expects to submit a clinical application
for CD24 monoclonal antibody ATG-031.

/ 16 /

I-Mab:

Pioneering the next generation of immuno-oncology

I-Mab currently has 14 clinical trials conducted in China and 8 trials in the United States, involving more than 1,000 patients
worldwide.
Among them, the phase III clinical trial of TJ1O1 targeting CD47 for the treatment of myelodysplastic syndrome has been initiated, and the trial for the treatment of solid tumors is in the phase II clinical stage
.

In 2023, etan growth hormone is expected to complete phase III clinical trials
.
TJD5, which targets CD73, is expected to begin pivotal clinical trials
in 2023.

At the same time, between 2023 and 2025, I-Mab expects to enter into more pharmaceutical companies, with 2 more products filed and 5-6 drugs filed for clinical
trials.

/ 17 /

Keyue Pharmaceutical:

To be a complement medicine with China's advantage

Keyue Medicine is a company dedicated to the research and development of complement targeted therapies for the treatment of immune-mediated diseases
.
With its LOGIC drug discovery platform, the company is committed to advancing world-first therapies (FICs) and best-in-class therapies （BIC）
。

Keyue Pharmaceutical's flagship products are for Factor H and C5's dual-target candidate KP104, which is also the world's first bifunctional complement inhibitory drug, can block both the classical complement pathway and the bypass pathway
.

In August 2022, the preclinical data of KP104 presented by Keyue Medicine at the 18th European Conference on Complement and Human Diseases (EMCHD) showed that KP104 is able to effectively block the dual complement replacement and terminal pathways, with ideal pharmacokinetic and pharmacodynamic characteristics
.

In December 2022, the Phase II clinical trial application of KP104 for the treatment of kidney diseases including IgA nephropathy and C3 glomerular disease has been approved
by the National Food and Drug Administration and the Australian Medicines Administration.
Key proof-of-concept data
for KP104 expected in 2023.

/ 18 /

Faith Medicine:

Focus on AAV gene therapy

Founded in 2018, Belief Pharma is a domestic company
dedicated to gene therapy through adeno-associated virus (AAV).
Belief Pharma is committed to using AAV technology to provide more effective and innovative gene therapies
for genetic defective genetic diseases, neurodegenerative diseases, age-related degenerative diseases and some major malignant diseases.

The AAV gene therapy drug BBM-H901 injection developed by Faith Pharma has been approved for clinical trials in China and has been included in the breakthrough therapy variety, which is intended to be used to prevent bleeding
in adult male patients with hemophilia B.
In addition, in 2023, Faith Pharma plans to open an IPO
.

/ 19 /

Insilico: Diversified product pipeline

Founded in 2014, Insilico is a clinical-stage drug discovery company driven by end-to-end artificial intelligence (AI) with a focus on cancer, fibrotic diseases, immune diseases, central nervous system diseases, aging-related diseases and more
.

Insilico has more than 30 self-developed pipelines, including 3CL protease inhibitors, "synthetically lethal" anti-tumor therapies targeting MAT2A and USP1, respectively
.
Among them, the fastest progress of anti-fibrosis projects has entered the phase 1 clinical trial stage in New Zealand and China
.
furthermore Insilico has reached relevant cooperation
with 9 global pharmaceutical companies, including Sanofi and Fosun Pharma.

At the JPM conference, Dr.
Alex Zhavoronkov, founder and CEO of Insilico, was invited to attend and share the progress
of the 6th generation intelligent robot laboratory and the company's leading IPF project.

/ 20 /

Laekna Pharmaceutical:

Bringing breakthrough therapies to cancer and liver fibrosis patients worldwide

Founded in 2016 to bring breakthrough therapies to cancer and fibrosis patients worldwide, Laekna Pharma is developing
14 innovative product candidates in its pipeline.

At present, Laekna has two potential core products
.
A highly selective ATP-competitive AKT inhibitor, LAE002, which is being developed for the treatment of ovarian, prostate, breast cancer, and solid tumors
resistant to PD-1/PD-L1 therapy.
The other is a next-generation androgen synthesis inhibitor called LAE001, which can simultaneously inhibit CYP17A1 and CYP11B2, and is being developed for the treatment of prostate cancer
.

/ 21 /

BICHEN Pharmaceutical:

Focus on the development of small molecule drugs that can break through the blood-brain barrier

Founded in 2015, BICHEN focuses on the research and development of small molecule drugs that can break through the blood-brain barrier, the founder and CEO of the company is Dr.
Chen Chen, and the co-founder and COO is Mr.

Huang Qing.

Through its transcerebral kinase drug discovery platform, Pichen has established a rich pipeline of in-brain drug development, and intends to develop indications focused on cancers with high incidence of brain metastases, including melanoma, lung cancer, colorectal cancer, etc
.

ABM-1310, the company's BRAF kinase activity inhibitor, obtained the US FDA and China NMPA clinical trial approval in November 2019 and November 2021, respectively, and the clinical phase I trial is progressing smoothly; On October 12, 2022, ABM-168, a MEK1/2 inhibitor that can be used in the brain, was approved for clinical use in the United States, and will recruit patients with advanced solid tumors, especially complicated brain metastases or primary brain
tumors.

Several other early-stage projects of the company are actively advancing by targeting the SRC/STAT3 and Wnt/b-catenin signaling pathways and inhibiting the cancer metastasis signaling pathway
.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.